VCA Stocks

Protiva Biotherapeutics Inc. announced today the completion of a convertible debenture financing with commitments of CAD$3.5 million. This fourth round of financing brings Protiva’s cumulative venture capital financing to CAD$26.2 million. Protiva Biotherapeutics Inc. is focused on the development of nucleic acid based pharmaceutical products to fight serious human diseases, such as cancer, influenza (including H5N1), Ebola, inflammatory diseases and chronic viral infections. Protiva’s proprietary Stable Nucleic-Acid Lipid Particle (SNALP) technology is an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. It represents a breakthrough in the field of RNA interference.